Update on the project
 Tumor Mutation Burden (TMB): from Recommendations for Testing to EQA Schemes


Conflicting results have been reported on the potential role of Tumor Mutational Burden (TMB) as predictive biomarker for immune checkpoint inhibitors. However, the recent approval of TMB as agnostic biomarker for pembrolizumab in previously treated patients with solid tumors is increasing the interest of laboratories to provide this test. In this scenario, the harmonization of read more…

Welcome back to NordiQC. Now offers PD-L1 IHC Fit-For-Purpose Proficiency Testing

PD-L1 IHC testing has a significant impact on patient eligibility for tailored specific immune oncology and require high diagnostic accuracy. This also underlines the need of appropriate EQA methods to evaluate the performance of PD-L1 IHC testing among the participating laboratories. At present, PD-L1 IHC testing is based on the “3D-approach” aligning Drug, Disease and read more…

Our Experience during the Covid-19 Pandemic, by IQNPath Board Member Jingxin Qiu

Jingxin Qiu, Roswell Park Comprehensive Cancer Center, Buffalo, New York I’d first like to share a bit of background about our center. Roswell Park Comprehensive Cancer Center was established by Dr. Roswell Park in 1898 in Buffalo, New York — the first institution in the world to focus exclusively on cancer research. Over the years, Roswell read more…